Melatonin and Cancer: The Oncostatic Hormone You Make Every Night

Melatonin is best known as the hormone that regulates the sleep-wake cycle — produced by the pineal gland in darkness, suppressed by light. But melatonin is far more than a sleep signal. It is also a potent antioxidant (more powerful than vitamins C and E in some assays), an immunomodulator, and — increasingly — a recognised oncostatic (cancer-inhibiting) agent. The evidence for melatonin's anti-cancer properties comes from multiple converging lines of research: epidemiological studies of night-shift workers, laboratory studies of melatonin's direct effects on cancer cells, and a growing body of clinical trials in cancer patients.

The Night-Shift Worker Evidence. The most compelling epidemiological evidence for melatonin's anti-cancer role comes from studies of night-shift workers — people who work at night and sleep during the day, chronically suppressing nocturnal melatonin production. A 2001 study by Hansen et al. found that Danish night-shift nurses had a 50% higher risk of breast cancer than day-shift nurses. A 2007 IARC (International Agency for Research on Cancer) review concluded that 'shift work that involves circadian disruption is probably carcinogenic to humans' — a Group 2A classification. The World Health Organization's IARC has since classified night-shift work as a probable carcinogen. The proposed mechanism: melatonin suppression removes a key anti-proliferative signal from breast, prostate, and colorectal cells.

Mechanisms of Anti-Cancer Activity. Melatonin's anti-cancer mechanisms include: (1) Antioxidant activity — melatonin directly scavenges free radicals and upregulates antioxidant enzymes (superoxide dismutase, glutathione peroxidase), reducing oxidative DNA damage. (2) Anti-proliferative effects — melatonin inhibits cancer cell proliferation by modulating cell cycle progression (inhibiting cyclin D1 expression) and reducing IGF-1 signalling. (3) Pro-apoptotic effects — melatonin promotes apoptosis in cancer cells through mitochondrial pathways. (4) Anti-angiogenic effects — melatonin inhibits VEGF expression, reducing tumour blood vessel formation. (5) Immune modulation — melatonin enhances NK (natural killer) cell activity and T-cell function, improving immune surveillance of cancer cells. (6) Oestrogen modulation — melatonin inhibits oestrogen receptor expression and reduces aromatase activity — mechanisms particularly relevant to hormone-sensitive breast cancer.

Clinical Evidence in Cancer Patients. A 2005 meta-analysis by Mills et al. (Journal of Pineal Research) reviewed 10 RCTs of melatonin as an adjunct to cancer treatment and found a significant reduction in 1-year mortality (relative risk 0.66) across multiple cancer types. A 2012 Cochrane review of melatonin in cancer found that melatonin reduced 1-year mortality and tumour remission rates when used alongside chemotherapy or radiotherapy. The doses used in these trials were pharmacological (10–40mg/day) — far higher than physiological melatonin levels. These are promising findings, but the trials were small and methodologically heterogeneous. Larger, well-controlled trials are needed before melatonin can be recommended as a standard adjunct to cancer treatment.

Protecting Your Own Melatonin Production. The most evidence-based approach to melatonin and cancer prevention is protecting your own nocturnal melatonin production: (1) Sleep in complete darkness — even small amounts of light during sleep suppress melatonin. Use blackout curtains or a sleep mask. (2) Avoid screens and bright light after 9 PM — blue-spectrum light is the most potent melatonin suppressor. (3) Maintain a consistent sleep schedule — irregular sleep timing disrupts the circadian melatonin rhythm. (4) If you work night shifts: advocate for rotating rather than permanent night shifts; use blackout curtains during daytime sleep; consider melatonin supplementation (0.5–3mg) to support circadian rhythm. (5) Eat melatonin-rich foods: tart cherries, walnuts, tomatoes, and grapes contain small amounts of melatonin.